MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
22 mars 2022 06h05 HE
|
MannKind
DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
08 mars 2022 06h05 HE
|
MannKind
DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results
24 févr. 2022 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash...
Update on Tyvaso DPI™ New Drug Application
24 févr. 2022 06h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
21 févr. 2022 09h05 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its...
MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
10 févr. 2022 06h05 HE
|
MannKind
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
05 janv. 2022 06h10 HE
|
MannKind
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
05 janv. 2022 06h05 HE
|
MannKind
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind’s CEO appointed as a member of the Thirona...
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
06 déc. 2021 06h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Corporation Reports 2021 Third Quarter Financial Results
09 nov. 2021 16h05 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash...